CTI BioPharma Corp. (CTIC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Comparing side by side

CTI BioPharma Corp. (NASDAQ:CTIC) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CTI BioPharma Corp. 12.28M 4.32 44.51M -0.87 0.00
Regeneron Pharmaceuticals Inc. 6.71B 6.62 2.44B 18.46 20.46

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for CTI BioPharma Corp. and Regeneron Pharmaceuticals Inc.

Profitability

Table 2 shows us CTI BioPharma Corp. and Regeneron Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
CTI BioPharma Corp. -362.46% -77.4% -49.1%
Regeneron Pharmaceuticals Inc. 36.36% 25.9% 18.5%

Volatility & Risk

CTI BioPharma Corp.’s volatility measures that it’s 141.00% less volatile than Standard and Poor’s 500 due to its -0.41 beta. In other hand, Regeneron Pharmaceuticals Inc. has beta of 1.34 which is 34.00% more volatile than Standard and Poor’s 500.

Liquidity

CTI BioPharma Corp.’s Current Ratio and Quick Ratio are 3.6 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor Regeneron Pharmaceuticals Inc. are 4 and 3.6 respectively. Regeneron Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to CTI BioPharma Corp.

Analyst Ratings

CTI BioPharma Corp. and Regeneron Pharmaceuticals Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CTI BioPharma Corp. 0 0 0 0.00
Regeneron Pharmaceuticals Inc. 0 3 2 2.40

Regeneron Pharmaceuticals Inc. on the other hand boasts of a $412.33 average target price and a 0.94% potential upside.

Institutional & Insider Ownership

The shares of both CTI BioPharma Corp. and Regeneron Pharmaceuticals Inc. are owned by institutional investors at 62.1% and 73.7% respectively. Insiders held 0.1% of CTI BioPharma Corp. shares. Competitively, insiders own roughly 0.4% of Regeneron Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CTI BioPharma Corp. -11.9% -14.45% -23.32% -69.86% -43.94% -44.78%
Regeneron Pharmaceuticals Inc. 3.27% 3.66% -4.42% 21.04% 1.07% 0.43%

For the past year CTI BioPharma Corp. has -44.78% weaker performance while Regeneron Pharmaceuticals Inc. has 0.43% stronger performance.

Summary

On 12 of the 12 factors Regeneron Pharmaceuticals Inc. beats CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrenÂ’s. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor. It also has collaboration agreements with Intellia Therapeutics, Inc. to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development; and the U.S. Department of Health and Human Services to develop treatments combating infectious diseases. The company was founded in 1988 and is headquartered in Tarrytown, New York.